U.S. stock futures fell on the last trading day of 2025, continuing a three-day decline for major benchmarks. Notable stock movers included Vanda Pharmaceuticals (VNDA), which saw a significant gain of 32.01% after receiving FDA approval for its drug NEREUS (tradipitant).